Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
March 29, 2023 16:05 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData...
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
March 14, 2023 16:30 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
February 28, 2023 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics to Present at February Investor Conferences
February 01, 2023 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment...
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 14, 2022 16:43 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of...
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
November 07, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
November 01, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022 07:30 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy...